GAM
BEAM icon

Gotham Asset Management’s Beam Therapeutics BEAM Stock Holding History

Gotham Asset Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-14,932
Closed -$493K – 1421
2024
Q1 		$493K Buy
+14,932
New +$465K 0.01% 1058

Other funds holding BEAM

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Gotham Asset Management's BEAM Position: Q2 2024 in Review

Gotham Asset Management sold out of Beam Therapeutics (BEAM) in Q2 2024, closing a stake of 14,932 shares — an estimated $493K sold.

Gotham Asset Management first reported a position in BEAM in Q1 2024 and held it in 1 quarter. The position peaked at $493K in Q1 2024. 214 funds tracked by Wall St. Rank hold BEAM as of Q2 2024.

  • Gotham Asset Management reported no remaining Beam Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Gotham Asset Management sold 14,932 Beam Therapeutics shares in Q2 2024, an estimated $493K.
  • Gotham Asset Management first reported a position in Beam Therapeutics in Q1 2024 and held it in 1 quarter.
  • Gotham Asset Management's Beam Therapeutics position peaked at $493K in Q1 2024.
  • 214 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2024.

Based on Gotham Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.